Monthly Itraconazole Versus Classic Homeopathy for Treatment of Recurrent Vulvovaginal Candidiasis (RVVC)
Launched by MEDICAL UNIVERSITY OF VIENNA · May 7, 2009
Trial Information
Current as of August 28, 2025
Completed
Keywords
ClinConnect Summary
Objective:
Antimycotics effectively treat sporadic and recurrent vulvovaginal candidiasis (RVVC). Classic homeopathy (CH) is also used to treat this condition. We compared the efficacy of CH and itraconazole in reducing the frequency of RVVC episodes.
Design:
Single-centre, prospective, randomized.
Sample:
One-hundred-and-fifty patients with a history of RVVC and an acute episode of VVC.
Methods:
Women were randomised into 3 groups: itraconazole with lactobacilli (group 1), itraconazole without lactobacilli (group 2) and CH (group 3). Itraconazole treatment of acute infection was fol...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Patients over 18 years, premenopausal
- • Negative pregnancy test
- • Signed informed consent
- • At least 4 Episodes of Candidiasis within the last year
- • Candida detectable by culture
- • Negative Hepatitis- and HIV-Serology
- • No Allergy to Itraconazole
- Exclusion Criteria:
- • Under 18 years
About Medical University Of Vienna
The Medical University of Vienna is a leading research institution dedicated to advancing healthcare through innovative clinical research and education. Renowned for its commitment to excellence in medical science, the university fosters interdisciplinary collaboration among researchers, clinicians, and academic professionals. Its clinical trials encompass a wide range of medical disciplines, aiming to develop cutting-edge therapies and improve patient outcomes. With state-of-the-art facilities and a strong emphasis on ethical standards, the Medical University of Vienna is at the forefront of transforming scientific discoveries into practical applications that enhance global health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Vienna, , Austria
Patients applied
Trial Officials
Armin Witt, MD
Principal Investigator
Vienna Medical School
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials